Please login to the form below

Not currently logged in
Email:
Password:

Michael Parini moves from Pfizer to Vertex

Will be the USbiotech's chief legal officer

Vertex Pharmaceuticals has appointed Michael Parini as executive vice president and chief legal officer. 

He joins Boston-based biotech company from Pfizer, where he served for more than a decade, in various leadership roles within the company's global legal team.

Most recently, he served as senior vice president and associate general counsel and was responsible for the strategic management of Pfizer's global litigation activities, including its civil, intellectual property, government and employment litigation.

He said: "I've watched Vertex's evolution over recent years and am thrilled to join this team at such an exciting and pivotal time in the company's history. I believe that Vertex is one of very few companies that has the potential to make a fundamental change in the treatment of many serious diseases.”

Parini will begin his role with Vertex on January 4, 2016, and will also serve as a member of its executive committee, reporting directly to Jeffrey Leiden,

Vertex's chairman, president and chief executive officer. Leiden said: "Michael brings to Vertex extensive global legal experience related to the development and commercialisation of multiple medicines.

“I welcome Michael to the Vertex team and believe his expertise will be invaluable as we bring our cystic fibrosis medicines to more people worldwide and advance key research and development programmes across many diseases.”

Prior to Pfizer, Parini served as a health care attorney at Akin, Gump, Strauss, Hauer & Feld, providing legal counsel on federal and state regulatory and policy issues.

1st December 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics